drugset / Trial / NCT00063973
Cilengitide in Treating Children With Refractory Primary Brain Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.
Timeline
- Start
- 2003-07
- Primary completion
- 2008-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cilengitide | Peptide | — | Intravenous |
Indications
benign meningioma
childhood brain stem glioma
childhood central nervous system germ cell tumor
childhood cerebellar astrocytic neoplasm
childhood cerebral astrocytoma
childhood choroid plexus neoplasm
childhood medulloblastoma
childhood oligodendroglioma
craniopharyngioma
ependymoblastoma
grade II meningioma
grade III meningioma
medulloepithelioma
mixed glioma
optic pathway glioma
pediatric infratentorial ependymoma
pediatric supratentorial ependymoma
pineoblastoma
subependymal giant cell astrocytoma
supratentorial primitive neuroectodermal tumor